Hospital
Hca Health Services of Virginia INC
Hca Health Services of Virginia INC was paid $64.62M by Medicaid between Jan 2018 and Dec 2024, across 317 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF VIRGINIA INC
RICHMOND, VA 23229
RICHMOND, VA 23229
33aNPI1194762294assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$64.62M
24GClaims1,439,968
24DCodes billed317
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#10 of 80
Median peer was paid$14.69M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 146,091 | $3.70M | |
| 2019 | 195,016 | $6.09M | |
| 2020 | 178,012 | $7.13M | |
| 2021 | 227,250 | $9.35M | |
| 2022 | 231,945 | $11.41M | |
| 2023 | 245,531 | $13.76M | |
| 2024incomplete | 216,123 | $13.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 123,154 | 102,044 | $20.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 64,312 | 53,720 | $9.99M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.1% | 23,602 | 20,864 | $3.93M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 14,702 | 12,742 | $2.51M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 12,710 | 11,044 | $2.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 11,317 | 10,059 | $2.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.8% | 5,606 | 5,035 | $1.78M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.5% | 2,660 | 2,467 | $1.63M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.3% | 8,510 | 7,820 | $1.46M |
| G0378 | Hospital observation service, per hour | 1.9% | 13,086 | 6,946 | $1.21M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 6,612 | 5,692 | $1.08M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 4,530 | 4,033 | $998K |
305 more codes
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.4% | 10,842 | $901K |
| 76818 | 1.3% | 11,879 | $855K | |
| 97598 | 1.2% | 1,343 | $798K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 2,458 | $762K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 2,973 | $512K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,229 | $497K |
| 58661 | <1% | 181 | $464K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 12,549 | $457K |
| 59025 | Fetal non-stress test | <1% | 2,470 | $404K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,448 | $399K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 569 | $381K |
| 97597 | <1% | 7,831 | $348K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,685 | $315K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,925 | $244K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,396 | $242K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 197 | $239K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,403 | $223K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 626 | $210K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,723 | $208K |
| 80053 | Comprehensive metabolic panel | <1% | 66,164 | $203K |
| 12001 | <1% | 1,013 | $200K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,214 | $200K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 248 | $192K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,361 | $181K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,482 | $175K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,145 | $173K |
| 76642 | <1% | 1,349 | $168K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,988 | $162K |
| 93971 | <1% | 2,111 | $160K | |
| 76801 | <1% | 3,387 | $158K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 177 | $156K |
| 76820 | <1% | 2,788 | $151K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,578 | $146K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,073 | $143K |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 1,126 | $142K |
| 10060 | <1% | 1,248 | $142K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,471 | $141K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 40,008 | $131K |
| 97602 | <1% | 679 | $124K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,777 | $120K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 719 | $116K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 38,449 | $110K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,395 | $106K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,697 | $105K |
| 76830 | Ultrasound, transvaginal | <1% | 1,651 | $104K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,550 | $99K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,175 | $91K |
| 97163 | <1% | 866 | $91K | |
| 71250 | <1% | 1,422 | $84K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21,651 | $82K |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 1,066 | $79K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 14,998 | $76K |
| 97162 | <1% | 1,129 | $75K | |
| 12011 | <1% | 363 | $66K | |
| 85027 | <1% | 92,824 | $65K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 70 | $65K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 511 | $57K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 279 | $54K |
| 74018 | <1% | 2,659 | $54K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 412 | $52K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,540 | $52K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,900 | $51K |
| 70486 | <1% | 1,125 | $51K | |
| 93970 | <1% | 526 | $49K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 194 | $47K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,679 | $47K |
| G0411 | Interactive group psychotherapy, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 588 | $47K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,189 | $47K |
| 97116 | <1% | 1,539 | $41K | |
| 83880 | <1% | 5,999 | $40K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,813 | $37K |
| 72131 | <1% | 666 | $34K | |
| 58558 | <1% | 13 | $34K | |
| 70491 | <1% | 149 | $31K | |
| 74174 | <1% | 85 | $31K | |
| 87040 | <1% | 4,526 | $30K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 605 | $29K |
| 84484 | <1% | 23,217 | $28K | |
| 97166 | <1% | 430 | $27K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,302 | $26K |
| 93017 | <1% | 121 | $24K | |
| 11043 | <1% | 180 | $22K | |
| 93325 | <1% | 184 | $21K | |
| 85379 | <1% | 5,412 | $20K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 283 | $20K |
| 74240 | <1% | 210 | $19K | |
| 54161 | <1% | 25 | $19K | |
| 70498 | <1% | 64 | $18K | |
| 73030 | <1% | 3,464 | $16K | |
| 12002 | <1% | 88 | $16K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $15K |
| 76821 | <1% | 527 | $14K | |
| 77065 | Tomosynthesis, mammo | <1% | 469 | $14K |
| 77066 | Tomosynthesis, mammo | <1% | 572 | $14K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $13K |
| 76770 | <1% | 106 | $13K | |
| 43235 | <1% | 26 | $13K | |
| 86850 | <1% | 6,626 | $13K | |
| 90715 | <1% | 746 | $13K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $13K |
| 80076 | <1% | 4,592 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,388 | $11K |
| 36430 | <1% | 31 | $11K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,836 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,697 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,881 | $10K |
| 90714 | <1% | 612 | $10K | |
| 88307 | <1% | 908 | $9K | |
| 72110 | <1% | 879 | $9K | |
| 78227 | <1% | 24 | $9K | |
| 96376 | <1% | 3,443 | $9K | |
| 97167 | <1% | 132 | $9K | |
| 72100 | <1% | 2,151 | $9K | |
| 83605 | <1% | 7,990 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 55 | $9K |
| 73562 | <1% | 2,676 | $9K | |
| 73130 | <1% | 2,910 | $8K | |
| 73564 | <1% | 1,526 | $8K | |
| 73610 | <1% | 3,528 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,813 | $8K |
| 81025 | <1% | 25,066 | $8K | |
| 73630 | <1% | 3,464 | $8K | |
| 86900 | <1% | 7,211 | $7K | |
| 83735 | <1% | 16,146 | $7K | |
| 81001 | <1% | 36,865 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,364 | $7K |
| 73110 | <1% | 1,956 | $7K | |
| 82565 | <1% | 6,146 | $7K | |
| 84702 | <1% | 7,166 | $6K | |
| 73502 | <1% | 1,686 | $6K | |
| 80051 | <1% | 4,008 | $6K | |
| 83690 | <1% | 22,154 | $6K | |
| 85610 | <1% | 11,736 | $6K | |
| 70496 | <1% | 42 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 23,082 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 203 | $5K |
| 76870 | <1% | 94 | $5K | |
| 76825 | <1% | 64 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,562 | $5K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 17,292 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,473 | $5K |
| 86901 | <1% | 7,202 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,131 | $4K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 130 | $4K |
| 81003 | <1% | 21,963 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,239 | $4K |
| 84703 | <1% | 6,716 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,761 | $4K |
| 80061 | Lipid panel | <1% | 1,480 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 548 | $3K |
| 76813 | <1% | 48 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,604 | $3K |
| 72141 | <1% | 13 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,360 | $3K |
| 29125 | <1% | 13 | $3K | |
| 87077 | <1% | 4,333 | $3K | |
| 85730 | <1% | 8,894 | $3K | |
| 73080 | <1% | 789 | $3K | |
| 73590 | <1% | 923 | $3K | |
| 87070 | <1% | 9,040 | $2K | |
| 72050 | <1% | 313 | $2K | |
| 76937 | <1% | 124 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 12,633 | $2K |
| 82553 | <1% | 383 | $2K | |
| 74019 | <1% | 311 | $2K | |
| 72170 | <1% | 527 | $2K | |
| 82947 | <1% | 3,999 | $2K | |
| 72040 | <1% | 255 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 16 | $2K |
| 71101 | <1% | 298 | $2K | |
| 76000 | <1% | 241 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,692 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 12,125 | $2K |
| 84100 | <1% | 2,801 | $2K | |
| 86140 | <1% | 874 | $2K | |
| 82550 | <1% | 3,249 | $2K | |
| 73140 | <1% | 864 | $2K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 15 | $2K |
| 93922 | <1% | 15 | $2K | |
| 85014 | <1% | 1,292 | $1K | |
| 71271 | <1% | 12 | $1K | |
| 97161 | <1% | 14 | $1K | |
| 84520 | <1% | 4,100 | $1K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 228 | $1K |
| 98960 | <1% | 13 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,986 | $1K |
| 74241 | <1% | 12 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,559 | $1K |
| 87205 | <1% | 3,787 | $1K | |
| A9270 | Non-covered item or service | <1% | 8,811 | $896.00 |
| 87486 | <1% | 52 | $858.82 | |
| 87210 | <1% | 4,947 | $851.64 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 103 | $817.31 |
| 73560 | <1% | 354 | $761.12 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,458 | $732.59 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,909 | $687.61 |
| 74022 | <1% | 231 | $670.47 | |
| 85018 | <1% | 1,253 | $665.41 | |
| 92523 | <1% | 18 | $657.93 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,019 | $628.46 |
| 73090 | <1% | 314 | $591.30 | |
| 88304 | <1% | 831 | $571.21 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 3,067 | $567.17 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,652 | $557.35 |
| 82570 | <1% | 822 | $556.63 | |
| 87340 | <1% | 329 | $520.22 | |
| 15853 | <1% | 30 | $518.54 | |
| 84112 | <1% | 16 | $485.88 | |
| 84439 | <1% | 190 | $481.67 | |
| 82803 | <1% | 590 | $475.50 | |
| 73552 | <1% | 38 | $472.68 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 64 | $457.41 |
| 87581 | <1% | 51 | $456.94 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,794 | $444.39 |
| J1815 | Injection, insulin, per 5 units | <1% | 3,648 | $393.60 |
| 87186 | <1% | 1,829 | $340.43 | |
| 88342 | <1% | 556 | $328.03 | |
| 86803 | <1% | 120 | $326.05 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,735 | $295.12 |
| 82150 | <1% | 324 | $291.07 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,690 | $270.60 |
| 87807 | <1% | 2,710 | $264.94 | |
| 84156 | <1% | 683 | $260.62 | |
| 51702 | <1% | 32 | $257.06 | |
| 84550 | <1% | 631 | $240.87 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,948 | $235.93 |
| 80047 | <1% | 111 | $226.88 | |
| 85652 | <1% | 207 | $217.74 | |
| 86923 | <1% | 31 | $217.14 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 85 | $211.38 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 119 | $208.55 |
| 87147 | <1% | 794 | $206.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,910 | $191.05 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,628 | $181.42 |
| 86920 | <1% | 17 | $166.62 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,757 | $166.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 113 | $161.70 |
| 73060 | <1% | 30 | $144.25 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,015 | $115.54 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,478 | $92.77 |
| 87088 | <1% | 353 | $68.15 | |
| 73620 | <1% | 43 | $66.84 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,213 | $66.26 |
| 73660 | <1% | 25 | $64.89 | |
| 88302 | <1% | 122 | $64.75 | |
| C1769 | Guide wire | <1% | 2,040 | $57.99 |
| 82040 | <1% | 57 | $57.33 | |
| 82248 | <1% | 215 | $55.26 | |
| J3490 | Unclassified drugs | <1% | 2,609 | $53.23 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 376 | $51.44 |
| 99152 | <1% | 159 | $38.98 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 799 | $36.62 |
| 82140 | <1% | 14 | $35.94 | |
| 88312 | <1% | 82 | $34.99 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,827 | $32.23 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 344 | $30.69 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,077 | $25.79 |
| 80197 | <1% | 35 | $22.35 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,295 | $15.46 |
| 85384 | <1% | 20 | $15.36 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 233 | $13.04 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,219 | $9.95 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 158 | $5.37 |
| 83615 | <1% | 29 | $3.24 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 26 | $2.98 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 29 | $2.83 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 512 | $2.31 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 74 | $2.16 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $1.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 183 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 116 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 580 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 370 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 177 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 25 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 656 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 26 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 40 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 62 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 137 | $0.00 |
| S4991 | Nicotine patches, non-legend | 0% | 63 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 170 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| S5000 | Prescription drug, generic | 0% | 29 | $0.00 |
| 90785 | 0% | 41 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 16 | $0.00 |
| 72070 | 0% | 12 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 3,698 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 31 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 58 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 12 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 32 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 84 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 117 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 17 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 15 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 14 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 96 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 19 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 22 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 21 | $0.00 |
| 86308 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDENTON, CHRISTOPHER (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hca Health Service of Virginia, INC. | Mechanicsville, VA | $1.63M |
| Hca Health Services of Virginia, INC. | Richmond, VA | $153K |
| Heartwood Therapeutics | Bend, OR | $27K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.